Synergy of sarcopenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis

Chu, Yi-ran; Xu, Shengqian; Wang, Jianxiong; Zong, He-Xiang; Chen, Keming; Tong, Wan-Qiu; Wang, Xi-le

doi:10.1007/s10067-022-06125-y

Cited by 8 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After contacting the authors, we learned that 4 studies included some overlap in their respective patient samples, so these studies were included only in descriptive analysis but excluded from pooled analysis. [20][21][22][23]…”

Section: Resultsmentioning

confidence: 99%

“…The duration of studies ranged from 7 to 58 months, with a median duration of 26.5 months. The country of origin of the greatest number of studies was China (6 studies), 7,[20][21][22][23]28 followed by Japan (5 studies), 24,25,[29][30][31] and Germany, 26 New Zealand, 32 South Korea, 33 Spain, 34 and Turkey 27 each with 1 study. Eight studies included both RA patients and healthy control subjects, and 8 studies [24][25][26][28][29][30][31]33 included RA patients only (see Supplementary Table 2, http://links.lww.com/RHU/A568).…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…Eight studies included both RA patients and healthy control subjects, and 8 studies [24][25][26][28][29][30][31]33 included RA patients only (see Supplementary Table 2, http://links.lww.com/RHU/A568). Eight studies were rated as having low risk of bias, [20][21][22]25,29,[33][34][35] and 8 studies with medium risk of bias. 23,24,[26][27][28][30][31][32] In addition, there may be a high risk of publication bias due to the limited number of studies published in this area (Fig.…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…Nine studies used criteria for both low muscle mass and low muscle functioning in their classification of sarcopenia, whereas 7 studies [20][21][22][23]28,32,35 used criteria only for low muscle mass. Eleven studies used criteria defined by the AWGS in their classification of sarcopenia, [20][21][22][23][24][25][28][29][30][31]35 representing 3127 patients.…”

Section: Sarcopenia In Ra Patientsmentioning

confidence: 99%

See 3 more Smart Citations

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Tam

Wong-Pack

Liu³

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

Sarcopenia is underrecognized in patients with rheumatoid arthritis (RA). Risk factors of sarcopenia and its impact on outcomes in RA patients are relatively unknown. We conducted a systematic review to identify factors and outcomes associated with sarcopenia in RA. We conducted this review according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. We searched PubMed, Embase, CINAHL, and Web of Science databases by combining the following search concepts: (1) RA and (2) sarcopenia. Articles were included if they included RA patients, assessed for sarcopenia using a consensus working group definition, and assessed for clinical outcomes. Meta-analysis was performed using studies that shared the same sarcopenia definition and consistency in reporting patient or disease variables. Our search identified 3602 articles. After removal of duplicates, title and abstract screen, and full-text review, 16 articles were included for final analysis. All studies had observational study designs. The pooled prevalence of sarcopenia ranged from 24% to 30%, depending on the criteria for sarcopenia used. Factors associated with sarcopenia included higher 28-joint Disease Activity Scale scores (+0.39; 95% confidence interval, +0.02 to +0.77) and baseline methotrexate use (odds ratio, 0.70; 95% confidence interval, 0.51-0.97). Baseline glucocorticoid use had a positive correlation with sarcopenia in multiple studies. Several studies found lower bone mineral density and higher incidence of falls and fractures in patients with sarcopenia. Sarcopenia is prevalent in RA, and it may be associated with higher RA disease activity, lower bone mineral density, and increased falls and fractures. Therefore, early screening of sarcopenia in RA patients is important to incorporate into clinical rheumatology practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of the Studiesmentioning

confidence: 99%

Section: Characteristics Of the Studiesmentioning

confidence: 99%

Section: Sarcopenia In Ra Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Tam

Wong-Pack

Liu³

et al. 2023

J Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…Osteoporosis is a clinical condition characterized by a progressive reduction in bone mass and a concomitant alteration in the skeletal microarchitecture, leading to a loss of bone strength, which increases the risk of fractures due to very mild trauma. Osteoporotic fractures mainly occur at the level of the vertebral bodies and the femoral neck [ 104 ]. There are essentially two forms of the disease: primary and secondary osteoporosis.…”

Section: Vitamin D and Osteoporosismentioning

confidence: 99%

The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies

et al. 2022

View full text Add to dashboard Cite

Background: Vitamin D exerts multiple beneficial effects in humans, including neuronal, immune, and bone homeostasis and the regulation of cardiovascular functions. Recent studies correlate vitamin D with cancer cell growth and survival, but meta-analyses on this topic are often not consistent. Methods: A systematic search of the PubMed database and the Clinical Trial Register was performed to identify all potentially relevant English-language scientific papers containing original research articles on the effects of vitamin D on human health. Results: In this review, we analyzed the antioxidant and anti-inflammatory effects of vitamin D against acute and chronic diseases, focusing particularly on cancer, immune-related diseases, cardiomyophaties (including heart failure, cardiac arrhythmias, and atherosclerosis) and infectious diseases. Conclusions: Vitamin D significantly reduces the pro-oxidant systemic and tissue biomarkers involved in the development, progression, and recurrence of chronic cardiometabolic disease and cancer. The overall picture of this review provides the basis for new randomized controlled trials of oral vitamin D supplementation in patients with cancer and infectious, neurodegenerative, and cardiovascular diseases aimed at reducing risk factors for disease recurrence and improving quality of life.

show abstract

Synergy or a third (causative) factor for fractures in rheumatoid arthritis?

Kara

Özçakar

2022

Clin Rheumatol

View full text Add to dashboard Cite

Synergy of sarcopenia and vitamin D deficiency in vertebral osteoporotic fractures in rheumatoid arthritis

Cited by 8 publications

References 40 publications

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

Risk Factors and Clinical Outcomes Associated With Sarcopenia in Rheumatoid Arthritis

The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies

Synergy or a third (causative) factor for fractures in rheumatoid arthritis?

Contact Info

Product

Resources

About